Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Recruitment Status

Active, not recruiting clinical trials

Status pages show live ClinicalTrials.gov search results by recruitment status, with direct links to official study records plus page-level filtering and sorting.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 7:58 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
10535
Shown on this page
12
Current sort
Recently updated
Status scope
Active, not recruiting
Additional filters apply within this recruitment status.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this status page

These controls apply only within Active, not recruiting. Default order is Recently updated. Add condition, location, sponsor, or therapy filters to narrow this status page further.

Reset status filters
Clear filters
Showing 1321–1332 of 10,535 matching trials with status Active, not recruiting.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Open in full search
Active, not recruiting Phase 2 Interventional

Vedolizumab for the Treatment of Collagenous Gastritis

NCT06317220
View directory record Official record
Conditions
Collagenous Gastritis
Interventions
Vedolizumab
Biological
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
14 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 29, 2026 · Synced Nov 14, 2026, 7:58 PM EST
Active, not recruiting Phase 2 Interventional

Phase 2 Study of Kylo-11 in ASCVD Patients With Elevated Lp(a)

NCT07327840
View directory record Official record
Conditions
Lipoprotein Disorder
Interventions
Kylo-11 or matched placebo
Drug
Lead sponsor
Kylonova (Xiamen) Biopharma co., LTD.
Industry
Eligibility
18 Years to 80 Years
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
18
States / cities
Los Angeles, California • Oxnard, California • San Diego, California + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2026 · Synced Nov 14, 2026, 7:58 PM EST
Active, not recruiting Phase 1Phase 2 Interventional

ALS20-101 Lentiviral Gene Therapy for Beta Thalassemia

NCT06364774
View directory record Official record
Conditions
Beta-Thalassemia
Interventions
ALS20
Biological
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
18 Years to 40 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 29, 2026 · Synced Nov 14, 2026, 7:58 PM EST
Active, not recruiting No phase listed Observational

Investigating the Mechanistic Effects of Mitapivat in Subjects With Sickle Cell Disease

NCT05675436
View directory record Official record
Conditions
Sickle Cell Anemia, Sickle Cell Thalassemia, Sickle Cell Pain, Hbss, Hbsc, Sickle Beta Thalassemia, Sickle Beta Zero Thalassemia, Sickle Cell Syndrome Variant
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
16 Years to 80 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 29, 2026 · Synced Nov 14, 2026, 7:58 PM EST
Active, not recruiting Phase 2 Interventional

An Open-Label Tirzepatide Trial for Comorbid Obesity and Stimulant Use Disorder

NCT07693608
View directory record Official record
Conditions
Obesity, Methamphetamine Use Disorder, Cocaine Use Disorder, Stimulant Use Disorders
Interventions
Tirzepatide
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 29, 2026 · Synced Nov 14, 2026, 7:58 PM EST
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Countermeasures to Circadian Misalignment

NCT04966351
View directory record Official record
Conditions
Circadian Rhythm Sleep Disorder of Shift Work Type, Metabolic Disease, Insulin Sensitivity
Interventions
Time-restricted feeding, Circadian Misalignment
Behavioral
Lead sponsor
Colorado State University
Other
Eligibility
18 Years to 35 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2030
U.S. locations
1
States / cities
Fort Collins, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 29, 2026 · Synced Nov 14, 2026, 7:58 PM EST
Active, not recruiting Phase 1Phase 2 Interventional

Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL

NCT03960840
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Diffuse Large B-cell Lymphoma, Acute Lymphoblastic Leukemia, Large B-cell Lymphoma
Interventions
Rapcabtagene autoleucel single agent, Ibrutinib
Biological · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
12
States / cities
Los Angeles, California • Stanford, California • Tampa, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2026 · Synced Nov 14, 2026, 7:58 PM EST
Active, not recruiting Phase 2 Interventional

Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity

NCT00092222
View directory record Official record
Conditions
Lymphoproliferative Disorder, HHV-8, Malignancy, HIV
Interventions
Etoposide, Interferon-alpha, Rituximab, Zidovudine, Liposomal Doxorubicin, Bortezomib, Valganciclovir, Doxorubicin, Vincristine, Cyclophosphamide, Filgrastim (G-CSF), Prednisone, Sirolimus, Observation Only
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2028
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 29, 2026 · Synced Nov 14, 2026, 7:58 PM EST
Active, not recruiting Not applicable Interventional Results available

CLIP-IT Post-Market Study

NCT06203054
View directory record Official record
Conditions
Left Atrial Appendage Exclusion
Interventions
Penditure™ Left Atrial Appendage (LAA) Exclusion System
Device
Lead sponsor
Medtronic Cardiac Surgery
Industry
Eligibility
18 Years and older
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
15
States / cities
Atlanta, Georgia • Chicago, Illinois • Carmel, Indiana + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2026 · Synced Nov 14, 2026, 7:58 PM EST
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers

PREVENT HPV -Related Cancers Trial

NCT07217145
View directory record Official record
Conditions
HPV Vaccination, Uptake Vaccination, Series Completion
Interventions
PREVENT
Behavioral
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
1,455 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 29, 2026 · Synced Nov 14, 2026, 7:58 PM EST
Active, not recruiting No phase listed Observational

A Study to Look at the Health Outcomes of Patients With COVID-19 and Influenza

NCT05160636
View directory record Official record
Conditions
COVID-19, Coronavirus Disease 2019, Influenza
Interventions
COVID-19 Vaccine
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
999 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 29, 2026 · Synced Nov 14, 2026, 7:58 PM EST
Active, not recruiting Not applicable Interventional

Transferring Speed of Processing Gains to Everyday Cognitive Tasks After Stroke

NCT05162781
View directory record Official record
Conditions
Stroke, Cognitive Dysfunction
Interventions
Speed of Processing Training, Instrumental Activities of Daily Living In-lab Training, Cognitive Transfer Packagke, Family Caregiver Coaching, Follow-up Phone Calls, Healthy Lifestyle In-lab Training, Healthy Lifestyle Transfer Package
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
40 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Oct 29, 2026 · Synced Nov 14, 2026, 7:58 PM EST